La catena delle opzioni mostra i dati chiave delle opzioni azionarie di FibroBiologics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per FibroBiologics..

FibroBiologics (NASDAQ:FBLG) Azioni, Catena delle Opzioni

FibroBiologics

FibroBiologics, Inc. - Common Stock

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

FibroBiologics Inc

News

AZPN

Emerson Proposes To Acquire Remaining Outstanding Shares Of AspenTech For $240 Per Share In Cash

Fiscal 2025 Guidance
Certain statements in this release, including without limitation, those in this section, are forward-looking statements. For additional information regarding the use and limitations of such statements, refer to "Cautionary Note Regarding Forward-Looking Statements" below.
Based on results for the first quarter of fiscal 2025 and its current outlook for the remainder of the fiscal year, the company is reaffirming the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">Fiscal 2025 Guidance Range [1] [2] (as of November 5, 2024)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Net Revenue:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Supply Chain Services</td>
<td colspan="1" rowspan="1">$560 million to $610 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Performance Services Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$370 million to $410 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Net Revenue Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$930 million to $1.02 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$235 million to $255 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$1.16 to $1.28</td>
</tr>
<tr>
<td colspan="2" rowspan="1">
Fiscal 2025 guidance is based on the realization of the following key assumptions:
<ul>
<li>Net administrative fees revenue of $495 million to $525 million, which includes $60 million to $75 million in revenue related to non-healthcare member purchasing</li>
<li>Supply Chain Services segment software licenses, other services and support revenue of $65 million to $85 million</li>
<li>Capital expenditures of $90 million to $100 million</li>
<li>Effective income tax rate in the range of 25% to 27%</li>
<li>Cash income tax rate of less than 5%</li>
<li>Free cash flow of 45% to 55% of adjusted EBITDA</li>
</ul>
</td>
</tr>
</tbody>
</table>
</figure>

Guidance

PINC

Premier Expects FY25 Net Revenue Of $930M-$1.02B Vs $977.19M Est, Adj EPS Of $1.16-$1.28 Vs $1.21 Est

Emerson Commences Review Of Strategic Options For Safety & Productivity Segment

JMP Securities analyst Jordan Bender upgrades Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) from Market Perform to Market Outperform and announces $5 price target.

Upgrades

Price Target

Analyst Ratings

CNTY

JMP Securities Upgrades Century Casinos to Market Outperform, Announces $5 Price Target

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $15.853 million which beat the analyst consensus estimate of $15.850 million by 0.02 percent. This is a 2.76 percent decrease over sales of $16.303 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

SOPH

Sophia Genetics Q3 2024 GAAP EPS $(0.28) Misses $(0.22) Estimate, Sales $15.853M Beat $15.850M Estimate

WIIM

Celanese shares are trading lower after the company reported worse-than-expected Q3 financial results and announced it intends to temporarily reduce its quarterly dividend.

Truist Securities analyst Jamie Cook downgrades Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and lowers the price target from $46 to $43.

Downgrades

CGNX

Truist Securities Downgrades Cognex to Hold, Lowers Price Target to $43

Buybacks

Emerson Reveals Increased Return of Capital To Shareholders With Plans To Repurchase Approximately $2B Of Shares In FY25; Expecting $1B In Fiscal Q1

Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) released its Q3 earnings on Thursday, October 24, 2024 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Boyd Gaming beat estimated earnings by 10.0%, reporting an EPS of $1.52 versus an estimate of $1.38.
Revenue was up $58.08 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.09 in the last quarter, resulting in a 4.0% increase share price change the following day.
Here's a look at Boyd Gaming's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.49</td>
<td>1.57</td>
<td>1.47</td>
<td>1.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.58</td>
<td>1.51</td>
<td>1.66</td>
<td>1.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>912.95M</td>
<td>909.06M</td>
<td>958.74M</td>
<td>930.47M</td>
<td>879.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>961.25M</td>
<td>967.51M</td>
<td>960.52M</td>
<td>954.41M</td>
<td>903.16M</td>
</tr>
</tbody>
</table>

<h3>Competitors' Recent Earnings Updates</h3>
It's important to consider Boyd Gaming's numbers in relation to how its competitors, like PENN Entertainment, Golden Entertainment, and Inspired Entertainment, have been performing.
<ul>
<li>PENN Entertainment announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.26, PENN Entertainment's actual EPS was $-0.18, reflecting a 30.77% increase.</li>
<li>Despite market projections of an EPS of $0.21, Golden Entertainment's earnings on August 08, 2024 fell short with an actual EPS of $0.02, representing a -90.48% decrease from expectations.</li>
<li>The latest earnings announcement from Inspired Entertainment on August 08, 2024 exceeded expectations, with an actual EPS of $0.2 compared to the market's estimate of $0.1, resulting in a 100.0% increase.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
The analysis presented here offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>October 24, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">1.52</td>
<td>10.14%</td>
<td>$64.31</td>
<td>$69.96</td>
<td>8.79%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.26</td>
<td style="text-align: right;">-0.18</td>
<td>30.77%</td>
<td>$18.72</td>
<td>$18.83</td>
<td>0.59%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.21</td>
<td style="text-align: right;">0.02</td>
<td>-90.48%</td>
<td>$28.12</td>
<td>$27.42</td>
<td>-2.49%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.10</td>
<td style="text-align: right;">0.20</td>
<td>100.0%</td>
<td>$8.48</td>
<td>$8.39</td>
<td>-1.06%</td>
</tr>
</tbody>
</table>

<h3>Analyzing Peer Revenue Discrepancy: Estimated vs. Announced</h3>
Here's a comparison table presenting estimated and announced revenue figures for Boyd Gaming's peers. This comparison offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>912.95M</td>
<td>961.25M</td>
<td>5.29%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>1.66B</td>
<td>1.66B</td>
<td>0.18%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>174.60M</td>
<td>167.33M</td>
<td>-4.16%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>74.41M</td>
<td>75.60M</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Boyd Gaming <a href="https://www.benzinga.com/quote/BYD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Boyd Gaming Earnings Review: Q3 Summary

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent.

MITT

AG Mortgage Investment Q3 2024 Adj EPS $0.17 Beats $0.16 Estimate

NXPI

NXP Semiconductors shares are trading lower after the company issued soft guidance.

2024 Outlook
The company raised its 2024 outlook for organic revenue growth to reflect strong year-to-date performance. All other measures in the outlook were maintained.
The company's outlook for 2024 in the table below assumes constant currency rates and excludes the impact of any future acquisitions or dispositions that may occur during the remainder of the year. Thomson Reuters believes that this type of guidance provides useful insight into the anticipated performance of its businesses.
The company expects its fourth-quarter 2024 organic revenue growth to be approximately 5% and its adjusted EBITDA margin to be approximately 37%.
The company continues to operate in an uncertain macroeconomic environment, reflecting ongoing geopolitical risk, uneven economic growth and an evolving interest rate and inflationary backdrop. Any worsening of the global economic or business environment, among other factors, could impact the company's ability to achieve its outlook.
Reported Full-Year 2023 Results and Full-Year 2024 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Thomson Reuters</td>
<td colspan="1" rowspan="1">
FY 2023
Reported
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
2/8/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
5/2/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
8/1/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
11/5/2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue Growth</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">6.5% - 7.0%</td>
<td colspan="1" rowspan="1">~ 7.0%</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic Revenue Growth(1)</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6%</td>
<td colspan="1" rowspan="1">6.0% - 6.5%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">~7.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin(1)</td>
<td colspan="1" rowspan="1">39.3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 38%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate Costs</td>
<td colspan="1" rowspan="1">$115 million</td>
<td colspan="1" rowspan="1">$120 - $130 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">$1.9 billion</td>
<td colspan="1" rowspan="1">~ $1.8 billion</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Accrued Capex as % of Revenues(1)</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
<td colspan="1" rowspan="1">~ 8.5%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Depreciation &amp; Amortization of Computer Software
&nbsp;&nbsp;&nbsp; Depreciation &amp; Amortization of Internally
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed Software
&nbsp;&nbsp;&nbsp; Amortization of Acquired Software
</td>
<td colspan="1" rowspan="1">
$628 million
 $556 million
$72 million
</td>
<td colspan="1" rowspan="1">
$730 - $750 million
 $595 - $615 million
~ $135 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
<td colspan="1" rowspan="1">
Unchanged
 $580 - $600 million
~ $150 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense (P&amp;L)(2)</td>
<td colspan="1" rowspan="1">$164 million(2)</td>
<td colspan="1" rowspan="1">$150 - $170 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">$125 - $145&nbsp; million</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate on Adjusted Earnings(1)</td>
<td colspan="1" rowspan="1">16.5&nbsp;%</td>
<td colspan="1" rowspan="1">~ 18%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
</tbody>
</table>
</figure>

Thomson Reuters Affirms FY24 Sales Guidance Of $7.27B Vs. $7.28B Estimate

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) reported quarterly earnings of $1.74 per share which missed the analyst consensus estimate of $1.87 by 6.95 percent. The company reported quarterly sales of $260.900 million which missed the analyst consensus estimate of $264.467 million by 1.35 percent. This is a 4.07 percent increase over sales of $250.700 million the same period last year.

Enpro Q3 2024 Adj. EPS $1.74 Misses $1.87 Estimate, Sales $260.900M Miss $264.467M Estimate

PLTR

Palantir shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance above consensus estimates.

MNDO

MIND C.T.I. Q3 EPS $0.04 Down From $0.06 YoY, Sales $5.21M Down From $5.26M YoY

Truist Securities analyst Jamie Cook upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Hold to Buy and raises the price target from $133 to $173.

Truist Securities Upgrades MasTec to Buy, Raises Price Target to $173

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) lowers FY2024 Adj EPS guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 analyst estimate..

Enpro Lowers FY2024 Adj EPS Guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.36 by 41.67 percent. The company reported quarterly sales of $276.995 million which beat the analyst consensus estimate of $244.000 million by 13.52 percent. This is a 13.89 percent decrease over sales of $321.664 million the same period last year.

WLKP

Westlake Chemical Q3 2024 GAAP EPS $0.51 Beats $0.36 Estimate, Sales $276.995M Beat $244.000M Estimate

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) affirms FY2024 sales outlook from $65.00 million-67.00 million to $65.00 million-67.00 million.

Sophia Genetics Affirms FY2024 Sales Guidance to $65.00M-67.00M  VS Est. 65.66M

Biotech

Health Care

General

BEAM

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

FibroBiologics GAAP EPS of -$0.27

FibroBiologics files for 16.02M shares of common stock by selling shareholder

IPO Roundup: Pershing Square, Actuate Therapeutics and more

FibroBiologics GAAP EPS of $0.03 beats by $0.10

The latest announcement is out from FibroBiologics, Inc. (FBLG). FibroBiologics, Inc. sold 100,000 shares to GEM at $4.51 each, after a 10% discoun...

FibroBiologics Raises Funds Through Strategic Equity Sales to GEM

FibroBiologics (FBLG) announced new findings from its artificial thymus organoid program. Recent results from the artificial thymus organoid progra...

FibroBiologics announces updates for novel artificial thymus organoid technology

FibroBiologics, Inc. ( ($FBLG) ) has issued an announcement. FibroBiologics, Inc. announced the resignation of CFO Mark Andersen, effective by Nove...

FibroBiologics Announces Leadership Changes and New Appointments

H.C. Wainwright initiated coverage of FibroBiologics (FBLG) with a Buy rating and $12 price target FibroBiologics is a clinical stage biotechnology...

FibroBiologics initiated with a Buy at H.C. Wainwright

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Alphabet upgraded, Boeing downgraded: Wall Street's top analyst calls

Maxim Group analyst Michael Okunewitch maintained a Buy rating on FibroBiologics, Inc. (FBLG – Research Report) yesterday and set a price target of...

FibroBiologics: A Promising Investment in Immune Restoration and Biotech Innovation

AAPL

ACTU

AEIBU

AMIX

ANRO

BMRN

BOOT

CARM

DTSQU

FBLG

GOOG

GOOGL

GUTS

IVVD

LINE

LZMH

MBAVU

OSTX

PSHZF

QRVO

SPHAU

TZUP

VERI

Legal

Press Releases

FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology

FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology

FibroBiologics Engages Southern Star Research as CRO in Australia

FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

Comments

FibroBiologics

FibroBiologics (FBLG) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO